Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
Written By : Farhat Nasim
Published On 2024-10-23 09:59 GMT | Update On 2024-10-23 09:59 GMT
Bengaluru: Novo Nordisk's announced on Monday that an oral version of its drug semaglutide significantly lowered the risk of cardiovascular events in patients during a late-stage study.
The drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, non-fatal heart attack and stroke, by 14% compared to placebo, meeting the main goal of the trial.
The study tested the drug as an adjunct to standard of care in 9,650 patients with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease, the company said.
Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
The drugmaker said detailed results from the study will be presented at a scientific conference next year.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.